Forge Biologics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2020-01-01
- Employees
- 251
- Market Cap
- -
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT06308718
- Locations
- 🇺🇸
University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT05739643
- Locations
- 🇺🇸
Children's Hospital of Orange County (CHOC), Orange, California, United States
🇺🇸University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Gene Transfer Clinical Trial for Krabbe Disease
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT04693598
- Locations
- 🇺🇸
University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath